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Duchenne muscular dystrophy (DMD) is a chronic,
complex, genetic childhood disease affecting boys, where
sufferers typically die in their 20s. DMD is caused by
mutations in the dystrophin gene and trials are currently
underway with exon skipping, a therapy which works by
patching the mutation thereby allowing production of a
functional gene. The dystrophin gene contains 79 exons
and mutations can be found in one or more exons.
T r e a t m e n tm u s tb et a r g e t e dt ot h es p e c i f i ce x o nw h i c h
is at fault and each one therefore requires a different
exon skipping chemistry. The success of trials with exon
skipping will present patients and physicians with the
possibility of a personalised medicine and with that, a
number of ethical issues. Firstly, equity and harm by
omission. Exons for the most common mutations will
be tested first and researchers assert that conforming to
t h ee x i s t i n gr e g u l a t o r yp a t h w a yf o re v e r ye x o n ,i tw i l l
not be cost effective. This raises the real possibility of
those children with rarer exons being denied a poten-
tially lifesaving treatment. Secondly, if therapies are
developed for the rarer mutations, risk and uncertainty
become more difficult to assess. In some cases a boy
may be his own control in a RCT and the boundaries
between experiment and therapy become blurred.
Thirdly, justice and minimum entitlement: given that
minimum entitlement in this case is likely to be very
expensive (the comparable myozome therapy costs
$300,000 per person, per year), the distribution of lim-
ited health resources throughout a population is once
again under scrutiny. This paper aims to anticipate
these ethical issues with a view to helping researchers,
clinicians, regulators and patient organisations to find
ways to ensure that the development of these life-saving
therapies progresses.
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